Tuesday, November 5, 2024

With Support from AWS, Yseop Develops a Unique Generative AI Application for Regulatory Document Generation Across BioPharma

Related stories

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci Corporation a data-first generative AI drug creation company, and...

GreyNoise Intelligence Discovers Zero-Day Vulnerabilities in Live Streaming Cameras with the Help of AI

GreyNoise Intelligence, the cybersecurity company providing real-time, verifiable threat...

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Medidata, a Dassault Systèmes brand and leading provider of...

Blend Appoints Mike Mischel as SVP of AI Consulting

Blend, a leader in data science and AI-powered solutions,...

Patronus AI Launches Industry-First Self-Serve API for AI Evaluation and Guardrails

Patronus AI announced the launch of the Patronus API, the first...
spot_imgspot_img

Yseop, a world leading Artificial Intelligence (AI) software company and pioneer in Generative AI, with support from Amazon Web Services (AWS), announced the development of an enhanced Generative AI application for the Biopharma industry. Yseop, a member of the AWS Partner Network (APN), has leveraged AWS for its security and scalability from day one and is now expanding its use to benefit its Large Language Model (LLM) ecosystem, infrastructure and tech expertise. Yseop, with the support of AWS, is empowering the world’s top Biopharma companies to bring pharmaceuticals and vaccines to market even faster.

Using AWS, Yseop is now able to embed LLM models for generating broader scientific content while meeting the security requirements of the pharmaceutical industry. Ultimately, with AWS and Yseop, scientific and medical writers within the world’s largest pharma companies can supercharge their productivity and accelerate the speed at which therapeutics get into the hands of those who need them most.

“Yseop has built a unique Generative AI platform for regulatory document generation that can increase the rate at which new drugs are introduced, while addressing top concerns like security, performance, and data localization” said Emmanuel Walckenear, CEO of Yseop. “Our work with AWS helps us tremendously and solidifies our leadership position further. With the profound infrastructure from AWS, we show existing and future clients that Yseop is working with proven solutions, and we greatly value our collaboration with them.”

Also Read: Deep 6 AI and Magnolia Market Access Partner to Accelerate Real-World Evidence (RWE) Projects for Life Sciences Companies and Healthcare Organizations

“Yseop and AWS are working together to democratize access to generative AI and deliver a unique business value to the life sciences sector, while navigating challenges like scalability and trust.” said Miguel Alava, AWS Managing Director, Software Companies EMEA. “Yseop can now leverage capabilities like Amazon Sagemaker and Amazon Bedrock to meet the strict AI software and data requirements across Biopharma.”

Key benefits through Yseop with AWS in Biopharma:

  • Accelerate time-to-value through a ready to go SaaS enterprise platform powered by AWS
  • Scale content generation safely across organizations thanks to AWS managed services and tooling – Amazon EKS, Amazon RDS and Infrastructure as Code CDK
  • Manage end-to-end data and document flows with enhanced security features
  • Benefit from the latest advanced AI capabilities with a model agnostic SaaS powered by AWS SageMaker, AWS Inferentia and AWS EC2

AWS provides Yseop and its clients with a fully managed, private cloud environment, which is of the highest importance in the regulated life science industry.

Source: GlobeNewsWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img